Jennifer M Radin1, Anthony W Hawksworth2, Patrick J Blair2, Dennis J Faix3, Rema Raman4, Kevin L Russell5, Gregory C Gray6. 1. Operational Infectious Diseases Department, Naval Health Research Center Joint Doctoral Program in Public Health (Epidemiology), San Diego State University/University of California. 2. Operational Infectious Diseases Department, Naval Health Research Center. 3. Deployment Health Research Department, Naval Health Research Center. 4. Department of Family and Preventive Medicine, University of California, San Diego. 5. Armed Forces Health Surveillance Center, Silver Spring, Maryland. 6. College of Public Health and Health Professions Emerging Pathogens Institute, University of Florida, Gainesville.
Abstract
BACKGROUND: In late 2011, after a 12-year hiatus, oral vaccines against adenovirus types 4 (Ad4) and 7 (Ad7) were again produced and administered to US military recruits. This study examined the impact of the new adenovirus vaccines on febrile respiratory illness (FRI) and adenovirus rates and investigated if new serotypes emerged. FRI rates and their associated hospitalizations had markedly risen since vaccine production ceased in 1999. METHODS: From 1996 to 2013, the Naval Health Research Center conducted FRI surveillance at 8 military recruit training centers in the United States. During this period, 58 103 FRI pharyngeal swab specimens were studied, yielding 37 048 adenovirus-positive cases, among which 64% were typed. RESULTS: During the 2 years after reintroduction of the vaccines, military trainees experienced a 100-fold decline in adenovirus disease burden (from 5.8 to 0.02 cases per 1000 person-weeks, P < .0001), without evidence that vaccine pressure had increased the impact of adenovirus types other than Ad4 and Ad7. Although the percentage of type 14 increased following reintroduction of the vaccination, the actual number of cases decreased. We estimate that the vaccines prevent approximately 1 death, 1100-2700 hospitalizations, and 13 000 febrile adenovirus cases each year among the trainees. CONCLUSIONS: These data strongly support the continued production and use of Ad4 and Ad7 vaccines in controlling FRI among US military trainees. Continued surveillance for emerging adenovirus subtypes is warranted. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: In late 2011, after a 12-year hiatus, oral vaccines against adenovirus types 4 (Ad4) and 7 (Ad7) were again produced and administered to US military recruits. This study examined the impact of the new adenovirus vaccines on febrile respiratory illness (FRI) and adenovirus rates and investigated if new serotypes emerged. FRI rates and their associated hospitalizations had markedly risen since vaccine production ceased in 1999. METHODS: From 1996 to 2013, the Naval Health Research Center conducted FRI surveillance at 8 military recruit training centers in the United States. During this period, 58 103 FRI pharyngeal swab specimens were studied, yielding 37 048 adenovirus-positive cases, among which 64% were typed. RESULTS: During the 2 years after reintroduction of the vaccines, military trainees experienced a 100-fold decline in adenovirus disease burden (from 5.8 to 0.02 cases per 1000 person-weeks, P < .0001), without evidence that vaccine pressure had increased the impact of adenovirus types other than Ad4 and Ad7. Although the percentage of type 14 increased following reintroduction of the vaccination, the actual number of cases decreased. We estimate that the vaccines prevent approximately 1 death, 1100-2700 hospitalizations, and 13 000 febrile adenovirus cases each year among the trainees. CONCLUSIONS: These data strongly support the continued production and use of Ad4 and Ad7 vaccines in controlling FRI among US military trainees. Continued surveillance for emerging adenovirus subtypes is warranted. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio Journal: Biomedicines Date: 2022-08-22
Authors: Gurdeep Singh; Xiaohong Zhou; Jeong Yoon Lee; Mohammad A Yousuf; Mirja Ramke; Ashrafali M Ismail; Ji Sun Lee; Christopher M Robinson; Donald Seto; David W Dyer; Morris S Jones; Jaya Rajaiya; James Chodosh Journal: Virology Date: 2015-09-07 Impact factor: 3.616
Authors: Marie E Killerby; Faye Rozwadowski; Xiaoyan Lu; Mardea Caulcrick-Grimes; Lisa McHugh; Ann Marie Haldeman; Tara Fulton; Eileen Schneider; Senthilkumar K Sakthivel; Julu Bhatnagar; Demi B Rabeneck; Sherif Zaki; Susan I Gerber; John T Watson Journal: Open Forum Infect Dis Date: 2019-01-11 Impact factor: 3.835